Not Yet RecruitingNot Applicable

CHEmotherapy and Cognitive Deterioration in Patients With Operable Breast Cancer: Impact of Cognitive Rehabilitation (CHEMOFOG)

128 participantsStarted 2024-06-01

Plain-language summary

An interventional, non-pharmacological, monocentric study evaluating the effectiveness of cognitive rehabilitation in counteracting chemotherapy-induced cognitive impairment (CRCI) in women with operable breast cancer treated with neo-adjuvant therapy and/ or adjuvant therapy.

Who can participate

Age range18 Years – 75 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Signature of informed consent * Diagnosis of operable/operated breast cancer * Patients candidate to be treated with Neo/adjuvant chemotherapy Exclusion Criteria: * Previous chemotherapy treatments * Patients with Metastatic breast cancer * Patients affected by pathologies of the brain, head trauma, and intellectual disabilities * Patients affected by previous or current neurological and/or psychiatric disorders * Patients currently treated with psychopharmacological drug

What they're measuring

The effectiveness of a 10-week cognitive rehabilitation program

Timeframe: Neurocognitive evaluations will be performed at T0 (before chemotherapy program start), T1 (after 6 months from chemotherapy started), and T2 (after 12 months from chemotherapy started)

Trial details

NCT IDNCT06435559

SponsorFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-01

Contact for this trial

Ornella Garrone, MD

+390255032660 ornella.garrone@policlinico.mi.it

View on ClinicalTrials.gov More Breast Cancer trials